An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease

NCT05174039 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Batten Disease

Interventions

DRUG: Miglustat 100 milligrams (mg) Oral Capsule

Sponsor

Beyond Batten Disease Foundation

Collaborators

[object Object]